Bakara / 185. Ayet
شَهْرُ رَمَضَانَ الَّذ۪ٓي اُنْزِلَ ف۪يهِ الْقُرْاٰنُ هُدًى لِلنَّاسِ وَبَيِّنَاتٍ مِنَ الْهُدٰى وَالْفُرْقَانِۚ فَمَنْ شَهِدَ مِنْكُمُ الشَّهْرَ فَلْيَصُمْهُۜ وَمَنْ كَانَ مَر۪يضًا اَوْ عَلٰى سَفَرٍ فَعِدَّةٌ مِنْ اَيَّامٍ اُخَرَۜ يُر۪يدُ اللّٰهُ بِكُمُ الْيُسْرَ وَلَا يُر۪يدُ بِكُمُ الْعُسْرَۘ وَلِتُكْمِلُوا الْعِدَّةَ وَلِتُكَبِّرُوا اللّٰهَ عَلٰى مَا هَدٰيكُمْ وَلَعَلَّكُمْ تَشْكُرُونَ

Orucun farz kýlýndýðý ramazan ayý, insanlara hidâyet rehberi olup onlara doðru yolu gösteren ve hakký bâtýldan ayýrýcý en açýk delilleri ihtiva eden Kur'an'ýn indirildiði aydýr. Ýþte bu sebeple içinizden ramazan ayýna eriþen orucunu tutsun. Ancak hasta veya yolcu olup da oruç tutamayan kimse, tutamadýðý oruçlarý baþka günlerde tutsun. Allah sizin için kolaylýk diler, fakat zorluk dilemez. Bütün bunlar sayýyý tamamlamanýz, size doðru yolu gösterdiði için Allah'ýn yüceliðini tanýmanýz ve O'na þükretmeniz içindir.

L-NDDP as a Therapeutic Option

Başlatan Fussilet, Nisan 26, 2009, 02:41:47 ÖS

Fussilet

ADMiN
7,935
Nisan 26, 2009, 02:41:47 ÖS
L-NDDP as a Therapeutic Option

Roman Perez-Soler, M.D.
Professor of Medicine
Associate Director for Clinical Oncology and Transiational Research

Dear Dr. Garland,

The purpose of this letter is to inform you of a promising new experimental therapeutic option for patients with malignant mesothelioma. This study is sponsored by the FDA Orphan Drug Program and is being conducted at New York University Kaplan Cancer Center.

Malignant pleural mesothelioma affects about 3,000 Americans each year. As you know, there is no curative therapy for most patients with this disease. However, our results to date suggest that patients may benefit from this treatment.

The investigational agent is a liposomal formulation of a highly lipophilic platinum compound known as L-NDDP. It is administered intrapleurally and cleared very slowly from the pleural cavity, thus providing a very favorable depot effect. Moreover, its lipophilicity and creamy nature enhances its local tumor penetration. The dose currently used (450 mg/m²), produces negligible local and systemic toxicities. The initial Phase I study included 21 patients with malignant pleural effusions of various etiologies. Five had mesothelioma . Two out of these 5 failed systemic chemotherapy; however are alive at +5 years after treatment with L-NDDP (Clin. Cancer Res. 1:1369-1374, 1995). The current Phase II study has enrolled 20 patients; 61% have had documented pathologic complete remission on second thoracoscopy (Perez-Soler et al., Proceed ASCO 18(1626):421a, 1999).

Patients who have received previous chemotherapy are eligible if they have a free-flowing pleural effusion. Based on the known pharmacology of L-NDDP, patients with low burden of disease (tumor thickness < 1cm) appear to be the sub-set that may derive the highest benefit from this protocol.

For further information or to refer a patient, call (212) 263-8043 or (212) 263-6485.

Sincerely,

Roman Perez-Soler, M.D.
Professor of Medicine
Associate Director for Clinical Oncology and Transiational Research
içimdeki tüm putlarý kýrdým ve sana yöneldim Rabbim...
Bu geliþimi kabul et, beni benden al, beni sana baðýþla...
-Fussilet-
_____________________________________________
Bugün gam tekkegahýnda feda bir canýmýz vardýr
Gönül abdal-ý aþk olmuþ gelin kurbanýmýz vardýr
Çimende bülbülü gördüm yaman efgan ile söyler
Dili kahhar ile her dem gül-i handanýmýz vardýr

Urfalý Abdi

Oruç nedir?, Orucu Bozan Haller ,  Ramazan Orucu...

SMF 2.1.3 © 2022, Simple Machines, TinyPortal 2.2.2 © 2005-2022
Sayfa 0.118 saniyede 27 sorgu ile oluşturuldu.
Lithium theme by Bloc © 2017